ISDA

Entry Detail

PDB ID:

7N91

Keywords:

TRANSFERASE/INHIBITOR

Title:

P70 S6K1 IN COMPLEX WITH MSC2317067A-1

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2021-06-16

Release Date:

2022-07-06

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.00 Å

R-Value Free:

0.27

R-Value Work:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Ribosomal protein S6 kinase beta-1
Mutations:T412E
Chain IDs:A, B
Chain Length:340
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P23443 Pfam ID:PF00069, PF00433 EC:2.7.11.1

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
SEP	A	SER	modified residue
TPO	A	THR	modified residue

Ligand Molecules

1RJ

Primary Citation

Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.

DeSelm, L, Huck, B, Lan, R, Neagu, C, Potnick, J, Xiao, Y, Chen, X, Jones, R, Richardson, T.E, Heasley, B.H, Haxell, T, Moore, J, Tian, H, Georgi, K, Rohdich, F, Sutton, A, Johnson, T, Mochalkin, I, Jackson, J, Lin, J, Crowley, L, Machl, A, Clark, A, Wilker, E, Sherer, B, Goutopoulos, A.Show

J.Med.Chem. 64 14603 14619 (2021)

PMID: 34596404 DOI: 10.1021/acs.jmedchem.1c01087

Abstact

Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway. Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor. M2698 is kinase selective, possesses favorable physical, chemical, and DMPK profiles, is orally available and well tolerated, and displayed tumor control in multiple in vivo studies of PAM pathway-driven tumors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures